121 related articles for article (PubMed ID: 34469609)
1. Recent advances in the chromatographic determination of the most commonly used anti-hepatitis C drug sofosbuvir and its co-administered drugs in human plasma.
Abdel-Tawab MA; Abd El-Moghny MG; El Nashar RM
Biomed Chromatogr; 2022 Jan; 36(1):e5238. PubMed ID: 34469609
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study.
Cusato J; De Nicolò A; Boglione L; Favata F; Ariaudo A; Mornese Pinna S; Carcieri C; Guido F; Avataneo V; Cariti G; Di Perri G; D'Avolio A
J Antimicrob Chemother; 2018 Jun; 73(6):1659-1664. PubMed ID: 29509884
[TBL] [Abstract][Full Text] [Related]
3. Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection.
Sundaram V; Kowdley KV
Expert Rev Gastroenterol Hepatol; 2016; 10(1):13-20. PubMed ID: 26560449
[TBL] [Abstract][Full Text] [Related]
4. UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients.
Notari S; Tempestilli M; Fabbri G; Libertone R; Antinori A; Ammassari A; Agrati C
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1073():183-190. PubMed ID: 29276983
[TBL] [Abstract][Full Text] [Related]
5. Sofosbuvir plus daclatasvir with or without ribavirin for chronic hepatitis C infection: Impact of drug concentration on viral load decay.
Virlogeux V; Choupeaux L; Pradat P; Maynard M; Bailly F; Scholtès C; Gagnieu MC; Zoulim F
Dig Liver Dis; 2016 Nov; 48(11):1351-1356. PubMed ID: 27498075
[TBL] [Abstract][Full Text] [Related]
6. Validated RP-HPLC Method for Simultaneous Determination of Ribavirin, Sofosbuvir and Daclatasvir in Human Plasma: A Treatment Protocol Administered to HCV Patients in Egypt.
Youssef AA; Magdy N; Hussein LA; El-Kosasy AM
J Chromatogr Sci; 2019 Aug; 57(7):636-643. PubMed ID: 31063182
[TBL] [Abstract][Full Text] [Related]
7. A Review on Analytical Strategies for the Assessment of Recently Approved Direct Acting Antiviral Drugs.
Aboras SI; Abdine HH; Ragab MAA; Korany MA
Crit Rev Anal Chem; 2022; 52(8):1878-1900. PubMed ID: 34138669
[TBL] [Abstract][Full Text] [Related]
8. Does Therapeutic Drug Monitoring of Ribavirin in HCV Genotype 3 Treatment With Sofosbuvir and Ribavirin Still Have a Role?
Brochot E; Bodeau S; Duverlie G
Ther Drug Monit; 2015 Aug; 37(4):550-1. PubMed ID: 25525764
[No Abstract] [Full Text] [Related]
9. Simeprevir and sofosbuvir for treatment of hepatitis C infection.
Chopp S; Vanderwall R; Hult A; Klepser M
Am J Health Syst Pharm; 2015 Sep; 72(17):1445-55. PubMed ID: 26294237
[TBL] [Abstract][Full Text] [Related]
10. [Daclatasvir-sofosbuvir combination therapy for chronic hepatitis C virus infection: progress in clinical studies].
Lu J; Zhou HJ; Xie Q
Zhonghua Gan Zang Bing Za Zhi; 2018 Feb; 26(2):147-150. PubMed ID: 29804384
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
Lau G; Benhamou Y; Chen G; Li J; Shao Q; Ji D; Li F; Li B; Liu J; Hou J; Sun J; Wang C; Chen J; Wu V; Wong A; Wong CL; Tsang ST; Wang Y; Bassit L; Tao S; Jiang Y; Hsiao HM; Ke R; Perelson AS; Schinazi RF
Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):97-104. PubMed ID: 27917405
[TBL] [Abstract][Full Text] [Related]
12. Feasible TLC-Spectro-Densitometry Technique for Simultaneous Determination of Two Hepatitis C Antiviral Drugs, Sofosbuvir and Simeprevir: Application to Combined Pharmaceutical Dosage Forms and Human Plasma.
Mohammed BS; Derayea SM; Hamad AE
J Chromatogr Sci; 2021 May; 59(6):576-583. PubMed ID: 33822903
[TBL] [Abstract][Full Text] [Related]
13. Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.
Abraham GM; Spooner LM
Clin Infect Dis; 2014 Aug; 59(3):411-5. PubMed ID: 24748524
[TBL] [Abstract][Full Text] [Related]
14. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
Abdelaty LN; Elnaggar AA; Said AA; Hussein RRS
Curr Drug Saf; 2020; 15(1):53-60. PubMed ID: 31573893
[TBL] [Abstract][Full Text] [Related]
15. Sofosbuvir for treatment of chronic hepatitis C.
Kattakuzhy S; Levy R; Kottilil S
Hepatol Int; 2015 Apr; 9(2):161-73. PubMed ID: 25788194
[TBL] [Abstract][Full Text] [Related]
16. Efficient HPTLC-dual wavelength spectrodensitometric method for simultaneous determination of sofosbuvir and daclatasvir: Biological and pharmaceutical analysis.
Abo-Zeid MN; El-Gizawy SM; Atia NN; El-Shaboury SR
J Pharm Biomed Anal; 2018 Jul; 156():358-365. PubMed ID: 29753282
[TBL] [Abstract][Full Text] [Related]
17. A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.
Weisberg IS; Jacobson IM
Expert Opin Pharmacother; 2017 Apr; 18(5):535-543. PubMed ID: 28092171
[TBL] [Abstract][Full Text] [Related]
18. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
[TBL] [Abstract][Full Text] [Related]
19. Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and ribavirin.
Peterson D; Van Ermen A
Am J Health Syst Pharm; 2017 Jun; 74(12):888-892. PubMed ID: 28596225
[TBL] [Abstract][Full Text] [Related]
20. Reduction in warfarin effect associated with sofosbuvir-velpatasvir.
Rindone JP; Mellen CK
Am J Health Syst Pharm; 2017 Sep; 74(17):1308-1311. PubMed ID: 28842460
[No Abstract] [Full Text] [Related]
[Next] [New Search]
